The financials
Maze Therapeutics, Inc. by the numbers
Maze Therapeutics, Inc. (MAZE) reported revenue of $0 in Q2 2026 (quarter ended June 30, 2026). That came with net loss of $45M.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | n/a |
| Operating income | −$48M | −$36M | n/a |
| Net income | −$45M | −$34M | n/a |
| Diluted EPS | −$0.76 | −$0.77 | n/a |
Business Segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q1 2026Total $20.0M
Segment Latestyear on year
- US$20.0M$20.0Myear on year --